Cerillion PLC (CER) — Investment Research Note
Executive summary
Cerillion is a specialised UK-listed BSS/OSS software vendor selling billing, charging and CRM platforms to telecoms operators (c.70 customers in c.45 countries), with a product-centric SaaS model that stands apart from the services-heavy, bespoke incumbents. Over FY20–FY25 revenue roughly doubled from £20.8m to £45.4m while adjusted EBITDA margin expanded from 27.9% to a remarkable 50.9%, driven by increasing software-licence mix and operating leverage; however, FY26 has disappointed, with a 14 Sep 2026 profit warning cutting revenue guidance to £46–48m (vs. consensus £52.8m) and EBITDA margin to 43–45% (vs. 45.2%) as licence orders and expansions slipped. The single most important point for valuation today is whether those orders are genuinely deferred — in which case the record £82.1m back-order book, £271m pipeline and 50%-margin software licence model make the de-rated shares cheap — or whether this is the start of a structural slowdown.
Fair value estimate
- Methodology: mid-cycle normalised earnings multiple cross-checked with EV/EBITDA, anchored to the £82.1m back-order book and £32.5m net-cash balance.
- Key assumptions: FY27 revenue recovers to £50–55m (back-order book conversion plus modest new licence recognition); EBITDA margin reverts toward 46–48% (vs. H1 2026 trough of 34.5% and FY25 peak of 50.9%); valued at 10–12x EV/EBITDA (reasonable for scaled vertical SaaS with net cash) and 18–20x normalised earnings.
- Mid-cycle EBITDA: £23–26m → EV range £230m–£312m + £32m net cash → £262m–£344m equity.
- Fair value range: 900p – 1,170p per share (implied market cap £265m – £345m).
- Mid-point fair value: ~1,035p / ~£305m market cap.
- Vs. current £206.8m market cap at 670p → absolute upside ~55% to the mid-point (34% to the low end, 75% to the high).
Sector context
- Sector: Technology — Software, specifically vertical B2B SaaS for telecoms (BSS/OSS category).
- Quality profile: well above typical peers — gross margins ~80%, adjusted EBITDA margin 50.9% at FY25 peak, net cash, mid-single-digit to mid-teens growth. The business is capital-light, with ~70% recurring/subscription-adjacent revenue and multi-year customer tenure. 2025-11 final results
- Listed peers: Amdocs (NASDAQ:DOX) and CSG Systems (NASDAQ:CSGS) are the obvious scaled telecoms BSS peers; closer-size UK comparables include Beeks Financial Cloud and GB Group (not perfect fits — few UK-listed vertical-SaaS peers of similar scale).
Investment thesis
- Record back-order book and pipeline underpin a plausible FY27 recovery. Back-order book of £82.1m (+64% YoY) and new-customer pipeline at a record £271m provide multi-year revenue visibility; the £42.5m Omantel contract alone is the largest in the company's history 2026-06 interim results.
- Fortress balance sheet and shareholder-friendly capital returns. Net cash of £32.5m against a £207m market cap, zero meaningful debt, consistent ~17% annual dividend growth across the period, and discretionary buybacks demonstrate durable financial health through the downturn 2025-11 final results; 2026-06 interim results.
- Spectacular operating leverage will work in reverse during an upswing. Software licence revenue carries 80%+ gross margin; when revenue was growing 20–25% during FY21–FY23, adjusted EBITDA grew 31–81% YoY, with adjusted PBT rising 131% in FY21 alone 2023-11 final results. If the deferred FY26 orders simply slip into FY27, the margin snap-back could be dramatic.
Key risks
- Delayed orders may not fully return — contract timing is now the central question. Management attributed the FY26 shortfall to "delayed or deferred" orders including "software licence expansions and upgrades" 2026-09 full-year trading update, but there is no visibility into whether these are competitive losses, budget cuts at telco customers, or genuinely timing-related.
- Customer concentration and large-contract lumpiness. Customer No. 1 contributed £13.1m (29% of FY25 revenue) and Omantel will become similarly large; project-driven licence revenue creates significant period-on-period volatility, as the −38% H1 2026 EBITDA swing demonstrates 2025-11 final results; 2026-06 interim results.
- AI substitution risk is real at the margin, even if management disputes it. Management devoted an unusual amount of H1 2026 narrative to defending why telcos won't in-source BSS/OSS using AI tools 2026-06 interim results, which itself signals that the question is being asked by investors and customers; competitive pressure from AI-assisted builds by larger vendors (e.g. Amdocs) is a tangible risk.
Operating leverage
Cerillion exhibits textbook high operating leverage, and the FY20–FY25 record is one of the clearer examples on AIM. Gross margins run 78–81% 2024-11 final results; 2025-11 final results with the bulk of the cost base — R&D, central ops, management — essentially fixed. Services revenue carries lower margins but incremental software-licence revenue drops almost entirely to EBITDA; this is why FY21 revenue growth of 25% translated into a 131% adjusted PBT increase and 1,240bps of EBITDA margin expansion. Working the other way, H1 2026 revenue fell 14% but adjusted EBITDA fell 38% and EBITDA margin compressed 1,320bps to 34.5% 2026-06 interim results — the same leverage, inverted. The implication for a 10–20% revenue beat above management's current £46–48m FY26 guide is substantial: at the FY25 incremental margin pattern, each additional £1m of licence revenue could add £0.7–0.9m to EBITDA, meaning a £5–10m revenue surprise would plausibly expand EBITDA by £3.5–8m (an uplift of 15–40% on the guided FY26 base). The strategic footprint (India + Bulgaria operations) means fixed-cost expansion is being spread across lower-cost geographies, suggesting incremental margin could even exceed historical norms as the business re-scales.
Value-trap signals
- Modest signal: FY26 is the first reported year of revenue growth decelerating meaningfully (from +12% in FY24 to flat/slightly down), accompanied by a visible profit warning.
- Modest signal: Louis Hall (CEO, founder) sold £20m of stock via secondary placing at 1,500p in June 2025 — just months before the de-rating 2025-06 proposed secondary placing. He is subject to a 365-day lock-up but the timing in hindsight was prescient.
- No evidence of: declining revenue trend (still growing), rising debt, dividend cuts (dividend +15% in H1 2026 despite earnings decline), aggressive accounting (clean audit reports, strong cash conversion historically), related-party issues, or regulatory threats. No structural value-trap signals identified.
Earnings vs. expectations
Across the five-year window, Cerillion built a track record of consistent beats: FY20 and FY21 trading updates flagged results "ahead of market expectations"; FY22's October trading update stated adjusted PBT would be "materially ahead" of £10.1m consensus (actual £11.9m); FY23's October trading update stated results would be "meaningfully ahead" of £14.3m consensus (actual £16.8m); FY24's October 2024 update flagged results "comfortably ahead" of £17.9m consensus (actual £19.8m); FY25 trading update was "slightly ahead" of consensus £20.5m (actual £21.8m). This long sequence of beats broke abruptly in September 2026 with a material miss (FY26 revenue £46–48m vs. consensus £52.8m, EBITDA margin 43–45% vs. 45.2%) 2026-09 full-year trading update. Pattern: five consecutive years of modest-to-meaningful beats, broken by one material miss driven by order deferrals.
Conviction: 3 (moderate)
Anchors: (a) exceptionally clean, well-disclosed financials across five years with consistent definitions; (b) proven and durable margin structure makes mid-cycle normalisation estimates well-grounded; (c) record back-order book provides a tangible floor on near-term revenue.
Limiters: (a) the FY26 profit warning materially changes the trajectory and we cannot yet verify whether deferred orders are truly timing-related or indicative of a structural slowdown; (b) telco customer buying behaviour and macro backdrop in FY27 is the single swing factor on fair value, and we have little visibility beyond management's commentary.